Bortezomib‐containing induction regimens in transplant‐eligible myeloma patients
- 4 September 2013
- Vol. 119 (23) , 4119-4128
Abstract
BACKGROUND: The objective of this meta‐analysis in patients with myeloma was to test the hypothesis that the addition of bortezomib to induction therapy not only improves the depth of response but also improves post‐transplant progression‐free survival (PFS) and overall survival (OS) outcomes.METHODS: Phase 3 trials that randomized newly diagnosed, transplant‐eligible patients with myeloma to receive either a bortezomib‐containing induction regimen (BCIR) or a nonbortezomib‐containing induction regimen (NBCIR) were identified. Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) guidelines were adapted for data synthesis, and comprehensive meta‐analysis software was used to report pooled data as hazard ratios or odds ratios under a random‐effects model.RESULTS: Four published phase 3 trials that included 2169 patients were analyzed. The postinduction and post‐transplant pooled odds ratio for achieving a complete response/near complete response or a very good partial response or better and the overall response rate were higher with BCIR. The pooled hazard ratios for 3‐year PFS and OS were 0.71 (95% confidence interval, 0.60‐0.83; P < .00,001) and 0.79 (95% confidence interval, 0.66‐0.96; P = .014), respectively, favoring BCIR. The odds of developing selected grade ≥3 toxicities (peripheral neuropathy and varicella‐zoster virus reactivation) also were higher with BCIR.CONCLUSIONS: The current meta‐analysis demonstrated that BCIR results in an improved depth of response, which translates into improved post‐transplant PFS and OS outcomes despite a higher incidence of toxicity. This analysis supports the concept that the choice of induction regimen can influence post‐transplant outcomes such as PFS and OS. Cancer 2013;119:4119–4128. © 2013 American Cancer Society.Keywords
This publication has 23 references indexed in Scilit:
- Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trialBlood, 2011
- Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trialBlood, 2011
- Bortezomib Plus Dexamethasone Is Superior to Vincristine Plus Doxorubicin Plus Dexamethasone As Induction Treatment Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: Results of the IFM 2005-01 Phase III TrialJournal of Clinical Oncology, 2010
- Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myelomaBlood, 2010
- Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trialThe Lancet Oncology, 2010
- Single-Agent Bortezomib in Previously Untreated Multiple Myeloma: Efficacy, Characterization of Peripheral Neuropathy, and Molecular Correlations With Response and NeuropathyJournal of Clinical Oncology, 2009
- Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Thalidomide Plus Dexamethasone Compared With Dexamethasone As Initial Therapy for Newly Diagnosed Multiple MyelomaJournal of Clinical Oncology, 2008
- Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myelomaHaematologica, 2008
- High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple MyelomaNew England Journal of Medicine, 2003
- A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple MyelomaNew England Journal of Medicine, 1996